A heart drug that slows electrical signals in heart cells to calm racing rhythms
In short: Flecainide is a medicine that steadies rapid heartbeats by dampening electrical activity in heart muscle. It treats several kinds of fast rhythm, yet it does not lengthen life and is avoided in certain heart conditions. Its benefits and risks depend closely on a patient's heart health, which is why doctors weigh it carefully.
Flecainide is a class Ic antiarrhythmic drug, first licensed in the United States in 1985. It is sold as a generic medicine and was prescribed more than one million times in the United States in 2023. It can be swallowed or given by injection into a vein, and clinicians use it to prevent and treat heart rhythms that beat too quickly, including several supraventricular and some ventricular tachycardias.
The drug works by slowing the Nav1.5 sodium channel in the heart, which flattens the rising phase of the cardiac action potential. Its effect strengthens as the heart beats faster, a feature known as use-dependence, which is why it can help break a racing rhythm. It also inhibits ryanodine receptor 2, which can reduce the calcium signals that set off some arrhythmias, although the relative weight of these two actions is unclear.
The drug carries real limits. Its use does not lower the risk of death, and it is not recommended for people with structural or ischaemic heart disease. The Cardiac Arrhythmia Suppression Trial found higher mortality when flecainide was used to suppress extra beats after a heart attack, and that trial was stopped early. Other concerns include proarrhythmia, worsening of heart failure in people with reduced ejection fraction, and rare but serious poisoning that calls for intensive support.
Flecainide also has a diagnostic role: in people suspected of Brugada syndrome it may bring out characteristic ECG findings that clarify an uncertain case. Its safety in pregnancy has not been well studied. Overall it is a powerful tool whose value rests on careful patient selection.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Flecainide
To cite this card, link to https://intellectplus.co.uk/app/health-flecainide.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health, medicine and disease · More in Health · Latest · A–Z · All topics